Cholangiocarcinoma, Intrahepatic Clinical Trial
Official title:
a Single-arm Study of Combined Therapy Using Oxaliplatin and Gemcitabine Chemotherapy, Lenvatinib and Programmed Cell Death Protein 1 Antibody (JS001) for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma
Verified date | July 2021 |
Source | Shanghai Zhongshan Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
In this phase 2 study, the investigators aim to evaluate the effects and safety of combined therapy using oxaliplatin and gemcitabine chemotherapy, Lenvatinib and immune checkpoint inhibitor PD-1 antibody (JS001) for patients with advanced and unresectable intrahepatic cholangiocarcinoma
Status | Active, not recruiting |
Enrollment | 30 |
Est. completion date | November 10, 2021 |
Est. primary completion date | January 10, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. The patient must be required to sign an informed consent form; 2. age 18-75 years old, male or female; 3. Eastern Cooperative Oncology Group (ECOG) fitness status score (PS score) 0; 4. Child-Pugh score A; 5. Histopathologically confirmed intrahepatic cholangiocarcinoma; consent to provide previously stored tumor tissue specimens or fresh biopsy tumor lesions; 6. unresectable ICC patients; 7. Functional indicators of vital organs meet the following requirements a Neutrophils =1.5*109/L; platelets=100*109/L; hemoglobin=9g/dl; serum albumin=3g/dl; b Thyroid stimulating hormone (TSH) = 1 times the upper limit of normal value(ULN), T3, T4 are in the normal range; c bilirubin = 1.5 times ULN; Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) = 1.5 times ULN; d serum creatinine = 1.5 ULN, creatinine clearance rate = 60ml / min; 8. The subject has at least 1 measurable liver lesion or non-liver lesion (according to RECIST 1.1); 9. Non-lactating or pregnant women, contraception during or after 3 months of treatment. Exclusion Criteria: 1. pathological diagnosis of hepatocellular carcinoma, mixed liver cancer and other non-cholangiocarcinoma malignant tumor components; 2. patients who have received previous treatment with PD1 antibody, programmed death ligand -1 (PDL1) antibody or cytotoxic T lymphocyte-associated antigen-4 (CTLA4) antibody; 3. with other malignant tumors, except for fully treated non-melanoma skin cancer, cervical carcinoma in situ, and papillary thyroid carcinoma; 4. active tuberculosis infection. Patients with active tuberculosis infection within 1 year prior to enrollment; had a history of active tuberculosis infection more than 1 year before enrollment, did not receive formal anti-tuberculosis treatment or tuberculosis is still active; 5. Have an active, known or suspected autoimmune disease. Subjects who require only hormone replacement therapy for hypothyroidism and skin diseases that do not require systemic therapy may be enrolled; 6. previous interstitial lung disease, or (non-infectious) pneumonia and need oral or intravenous steroid therapy; 7. Long-term systemic hormones (dose equivalent to >10 mg prednisone/day) or any other form of immunosuppressive therapy are required. Subjects using inhaled or topical corticosteroids may be enrolled; 8. severe cardiopulmonary and renal dysfunction; 9. suffering from high blood pressure, and can not be well controlled by antihypertensive drugs (systolic blood pressure =140mmHg or diastolic blood pressure =90mmHg); 10. abnormal blood coagulation (PT>14s), with bleeding tendency or receiving thrombolytic or anticoagulant therapy; 11. hepatitis B virus (HBV) DNA>2000 copies/ml, hepatitis C virus (HCV) RNA>1000; 12. Significant clinically significant bleeding symptoms or a clear tendency to appear within 3 months prior to enrollment; 13. active infections requiring systemic treatment; 14. Human immunodeficiency virus (HIV) positive; 15. History of psychotropic substance abuse, alcohol abuse or drug abuse; 16. has a history of allergy to platinum; 17. Other factors that may influence the safety of the subject or the compliance of the test by the investigator. Serious illnesses (including mental illness), severe laboratory tests, or other family or social factors that require combined treatment. |
Country | Name | City | State |
---|---|---|---|
China | Zhongshan Hospital | Shanghai | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Shanghai Zhongshan Hospital |
China,
André T, Tournigand C, Rosmorduc O, Provent S, Maindrault-Goebel F, Avenin D, Selle F, Paye F, Hannoun L, Houry S, Gayet B, Lotz JP, de Gramont A, Louvet C; GERCOR Group. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol. 2004 Sep;15(9):1339-43. — View Citation
El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling TH Rd, Meyer T, Kang YK, Yeo W, Chopra A, Anderson J, Dela Cruz C, Lang L, Neely J, Tang H, Dastani HB, Melero I. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017 Jun 24;389(10088):2492-2502. doi: 10.1016/S0140-6736(17)31046-2. Epub 2017 Apr 20. — View Citation
Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Objective response rate | Objective response rate of advanced and unresectable intrahepatic cholangiocarcinoma in combination therapy | 12 months | |
Secondary | safety: the potential side effects | the potential side effects | 12 months | |
Secondary | overall survival | From the beginning date of combined therapy to the date of death | 12 months | |
Secondary | Progression free survival | From the beginning date of combined therapy to the date of disease progression | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT04077983 -
Nab-Paclitaxel Combined With Gemcitabine Adjuvant Chemotherapy After Radical Resection of Intrahepatic Cholangiocarcinoma
|
Phase 2 | |
Not yet recruiting |
NCT04527679 -
Cisplatin and Gemcitabine Chemotherapy and Lenvatinib for Patients With Unresectable Intrahepatic Cholangiocarcinoma
|
Phase 2 | |
Terminated |
NCT03267940 -
Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
|
Phase 1 | |
Recruiting |
NCT04634058 -
PD-L1 Antibody Combined With CTLA-4 Antibody for Patients With Advanced Intrahepatic Cholangiocarcinoma Who Progressed After Standard Treatment
|
Phase 2 | |
Completed |
NCT03377179 -
A Study of ABC294640 (Yeliva ®) Alone and in Combination With Hydroxychloroquine Sulfate in Treatment of Patients With Advanced Cholangiocarcinoma
|
Phase 2 | |
Active, not recruiting |
NCT04361331 -
Two-cohort Study of Toripalimab(PD1)+Lenvatnib, or Gemox+Lenvatinib in Advanced Intrahepatic Cholangiocarcinoma
|
Phase 2 | |
Completed |
NCT04072250 -
Surgery for Recurrent Intrahepatic Cholangiocarcinoma
|
||
Recruiting |
NCT05210322 -
Percutaneous Cholangiopancreatoscopy Registry
|
||
Recruiting |
NCT04782804 -
Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative Recurrence
|
Phase 1/Phase 2 | |
Recruiting |
NCT04264260 -
Evaluation the Palliative Effects of Colchicine on Primary Hepatic Malignant Tumors Unable to Receive Curative Treatment
|
Phase 2 | |
Recruiting |
NCT06140134 -
Liver Transplantation in Intrahepatic Cholangiocarcinoma
|
||
Enrolling by invitation |
NCT04195503 -
Liver Transplant for Stable, Advanced Intrahepatic Cholangiocarcinoma
|
N/A | |
Recruiting |
NCT04506281 -
PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors
|
Phase 2 | |
Recruiting |
NCT05124002 -
Recombinant Human Adenovirus Type 5 Plus HAIC of FOLFOX for Intrahepatic Cholangiocarcinoma
|
Phase 4 | |
Terminated |
NCT03316222 -
Study of GNS561 in Patients With Liver Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03405909 -
Standardized CEUS Algorithms for Diagnosis of HCC - Prospective German Multicenter Study
|
||
Recruiting |
NCT06381648 -
Detecting Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma (LyMIC)
|
||
Available |
NCT03414489 -
Expanded Access for the Treatment of Advanced Cholangiocarcinoma With ABC294640 (Yeliva ®)
|